Victory Capital Management
CHRS icon

Victory Capital Management’s Coherus Oncology CHRS Stock Holding History

Victory Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.8K Sell
13,426
-692
-5% -$1.13K ﹤0.01% 2446
2026
Q1 		$23.9K Buy
14,118
+2,283
+19% +$4.05K ﹤0.01% 2369
2025
Q4 		$16.8K Buy
+11,835
New +$17.2K ﹤0.01% 2395
2025
Q2 		– Sell
-13,416
Closed -$10.8K – 2488
2025
Q1 		$10.8K Sell
13,416
-262
-2% -$302 ﹤0.01% 2450
2024
Q4 		$18.9K Sell
13,678
-354
-3% -$397 ﹤0.01% 2449
2024
Q3 		$14.6K Sell
14,032
-112
-0.8% -$154 ﹤0.01% 2460
2024
Q2 		$24.5K Buy
14,144
+165
+1% +$332 ﹤0.01% 2414
2024
Q1 		$33.4K Sell
13,979
-327
-2% -$805 ﹤0.01% 2410
2023
Q4 		$47.6K Buy
14,306
+3,206
+29% +$8.59K ﹤0.01% 2439
2023
Q3 		$41.5K Sell
11,100
-1,040
-9% -$4.8K ﹤0.01% 2399
2023
Q2 		$51.8K Sell
12,140
-187
-2% -$1.1K ﹤0.01% 2382
2023
Q1 		$84.3K Sell
12,327
-2,782
-18% -$21.6K ﹤0.01% 2381
2022
Q4 		$120K Sell
15,109
-3
-0% -$23 ﹤0.01% 2337
2022
Q3 		$145K Buy
15,112
+1,333
+10% +$13.5K ﹤0.01% 2412
2022
Q2 		$100K Buy
13,779
+443
+3% +$3.85K ﹤0.01% 2461
2022
Q1 		$121K Buy
+13,336
New +$170K ﹤0.01% 2491
2021
Q4 		– Sell
-97,320
Closed -$1.56M – 2784
2021
Q3 		$1.56M Sell
97,320
-30,358
-24% -$445K ﹤0.01% 1677
2021
Q2 		$1.76M Sell
127,678
-4,837
-4% -$68.5K ﹤0.01% 1668
2021
Q1 		$1.94M Buy
132,515
+114,668
+643% +$1.95M ﹤0.01% 1658
2020
Q4 		$310K Buy
17,847
+3,737
+26% +$66.5K ﹤0.01% 2274
2020
Q3 		$259K Buy
+14,110
New +$262K ﹤0.01% 2214
2020
Q2 		– Sell
-10,154
Closed -$165K – 2653
2020
Q1 		$165K Sell
10,154
-1,250
-11% -$23.1K ﹤0.01% 2209
2019
Q4 		$205K Buy
11,404
+1,541
+16% +$28.4K ﹤0.01% 2307
2019
Q3 		$200K Buy
+9,863
New +$197K ﹤0.01% 2220

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Victory Capital Management's CHRS Position: Q2 2026 in Review

Victory Capital Management reduced its Coherus Oncology (CHRS) stake by 4.9% in Q2 2026, selling an estimated $1.13K and leaving 13,426 shares worth $18.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2446.

Victory Capital Management first reported a position in CHRS in Q3 2019 and has held it in 24 quarters since. The position peaked at $1.94M in Q1 2021. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Victory Capital Management held 13,426 shares of Coherus Oncology worth $18.8K as of Q2 2026.
  • Victory Capital Management sold 692 Coherus Oncology shares in Q2 2026, an estimated $1.13K.
  • Coherus Oncology made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2446 holding.
  • Victory Capital Management first reported a position in Coherus Oncology in Q3 2019 and has held it in 24 quarters since.
  • Victory Capital Management's Coherus Oncology position peaked at $1.94M in Q1 2021.
  • 146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.